Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma.
Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406.
T J
TJ
Torphy
G P
GP
Livi
J M
JM
Balcarek
J R
JR
White
F H
FH
Chilton
B J
BJ
Undem
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000235:genetics; D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000032:analysis / Q000494:pharmacology; D006801:Humans; D008407:Mast Cells / Q000187:drug effects; D051379:Mice; D011760:Pyrrolidinones / Q000494:pharmacology; D020889:Rolipram
D011760:Pyrrolidinones; D005576:Colforsin; D000242:Cyclic AMP; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases; D020889:Rolipram; D015056:1-Methyl-3-isobutylxanthine